Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 26, 2022BMC Cardiovascular DisordersOpen Access

Diagnosis, management, and outcome of cardiac sarcoidosis and giant cell myocarditis: a Swedish single center experience

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Cardiac sarcoidosis and giant cell myocarditis are rare conditions with overlapping similarities but distinct clinical and histopathological features, prompting a direct comparison of their demographics, clinical presentation, and outcomes.

Population

Adult patients with CS (n = 71) or GCM (n = 21)

Comparison

CS vs GCM

Design

Single-center retrospective comparative cohort study

Follow-up

Median 33.5 months for CS and 2.98 months for GCM

Authors

EBEmanuele BobbioCHClara HjalmarssonMBMarie Björkenstam

Discussion

Loading...

Member takes

Overview

GCM warrants closer surveillance than CS for rapid deterioration; leaves open whether etiology-tailored therapies alter outcomes.

Structured PICO

P
Population
92 adult patients with cardiac sarcoidosis (n = 71) or giant cell myocarditis (n = 21) diagnosed at a Swedish single center between 1991 and 2020.
O
Outcome
Composite endpoint of death or heart transplantation (HTx)composite

Giant cell myocarditis has a significantly more fulminant clinical course with higher rates of biventricular failure and need for heart transplantation or death compared to cardiac sarcoidosis.

Cite This Study

Bobbio et al. (2022) studied this question.

synapsesocial.com/papers/6a1bbff626cb5670aa9ccde3https://doi.org/10.1186/s12872-022-02639-0
View Full Paper
Ask AI
Bookmark
Share